Published: June 2024

Last updated: June 2024

Time and Cost Savings of Machine Learning and Artificial Intelligence in Systematic Reviews: A Case Study

INTRODUCTION: Conducting a systematic review (SR) of clinical trials is labor-intensive and expensive. However, existing open-source content can be used to develop custom machine learning tools suited to the workflow of individual organizations. This case study details the potential of a bespoke tool developed by York Health Economics Consortium (YHEC) for reducing the time and cost involved in producing an SR.

METHODS: RESbot is a flexible, stand-alone machine learning tool created using an extensively tested open-source dataset developed by Cochrane. The tool identifies randomized controlled trials (RCTs) from a large corpus of records. It has a user interface and inputs/outputs to fit into the company’s existing workflow at any stage. RESbot has two settings. The “sensitive” setting identifies a higher number of possible RCTs with a lower risk of missing eligible studies, while the “precise” setting is more focused. For both settings, we estimated the reduction in resources required for record screening in two examples of RCT-only reviews.

RESULTS: Scoping searches in MEDLINE were conducted for SRs of RCTs in femoropopliteal artery diseases (FAD) and postpartum depression (PD). The results were run through RESbot. For the FAD SR, 1,444 references were retrieved, with the sensitive and precise RESbot settings reducing the record set by 38 percent and 64 percent, respectively. For the PD SR, a record set of 2,153 records was reduced by 25 percent and 41 percent, respectively. Resource savings offered by RESbot vary depending on subject but may reduce the time taken to screen records by up to 64 percent, with a subsequent reduction in cost to the organization commissioning the SR.

CONCLUSIONS: The use of bespoke machine learning tools in SR production has the potential to reduce the time and staff costs involved in producing a review. This case study tested the effect on a small number of records, but for larger reviews retrieving tens of thousands of records, reductions in time and costs can be very significant.

You may also be interested in

Peer-reviewed publication

Reducing Opioid Use for Chronic Pain With a Group-Based Intervention: Economic Evaluation using Randomised Controlled Trial Data

YHEC authors: Joe Moss
Publication date: October 2026
Journal: Addiction

Abstract

BACKGROUND AND AIMS: Long-term strong opioid use for chronic non-malignant pain (CNMP) represents a significant public health challenge, associated with reduced health-related quality of life (HRQoL) and increased mortality. The...

Peer-reviewed publication

Methods in Systematic Reviews of Health Economic Evaluations in Submissions to Health Technology Assessment Agencies: How Systematic Are They, and Does This Matter?

YHEC authors: Chris Bartlett, Rachael McCool, Matthew Taylor
Publication date: October 2026
Journal: PharmacoEconomics

Abstract

Systematic reviews of health economic evaluations (SR-HEEs) are perceived as mandatory components of the health technology assessment (HTA) process in many jurisdictions. However, HTA agencies vary in how they prescribe...

Peer-reviewed publication

Commentary: Selpercatinib versus Multi-Kinase Inhibitors for Advanced Medullary Thyroid Cancer: A Network Meta-Analysis of RET-Targeted Therapies

YHEC authors: Joe Moss, Erin Barker
Publication date: October 2026
Journal: Frontiers in Endocrinology

Abstract

We have read with great interest the published network meta-analysis (NMA) by Wang et al. (2026) in Frontiers in Endocrinology, which synthesised available randomised controlled trial (RCT) evidence to evaluate...